Wind, Sven

Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant

Heumüller, S., Wind, S., Barbosa-Sicard, E., Schmidt, H. H. H. W., Busse, R., Schröder, K., & Brandes, R. P. (2008) · Hypertension

Nitric Oxide and Endothelin EffectsRedox biology and oxidative stress

Cited by 735

Comparative pharmacology of chemically distinct nadph oxidase inhibitors

Wind, S., Beuerlein, K., Eucker, T., Müller, H., Scheurer, P., Armitage, M., Ho, H., Schmidt, H., & Wingler, K. (2010) · British Journal of Pharmacology

Nitric Oxide and Endothelin EffectsRedox biology and oxidative stress

Cited by 241

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P. (2017) · Clinical Pharmacokinetics

HER2/EGFR in Cancer ResearchPharmacogenetics and Drug Metabolism

Cited by 206

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Yang, J. C.-H., Sequist, L. V., Zhou, C., Schuler, M., Geater, S. L., Mok, T., Hu, C.-P., Yamamoto, N., Feng, J., O'Byrne, K., et al. (2016) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 194

Oxidative Stress and Endothelial Dysfunction in Aortas of Aged Spontaneously Hypertensive Rats by NOX1/2 Is Reversed by NADPH Oxidase Inhibition

Wind, S., Beuerlein, K., Armitage, M. E., Taye, A., Kumar, A. H. S., Janowitz, D., Neff, C., Shah, A. M., Wingler, K., & Schmidt, H. H. H. W. (2010) · Hypertension

Nitric Oxide and Endothelin EffectsRedox biology and oxidative stress

Cited by 181

Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

Wind, S., Schmid, M., Erhardt, J., Goeldner, R.-G., & Stopfer, P. (2013) · Clinical Pharmacokinetics

HER2/EGFR in Cancer ResearchPharmacogenetics and Drug Metabolism

Cited by 94

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

Wind, S., Giessmann, T., Jungnik, A., Brand, T., Marzin, K., Bertulis, J., Hocke, J., Gansser, D., & Stopfer, P. (2014) · Clinical Drug Investigation

Pharmacogenetics and Drug MetabolismDrug Transport and Resistance Mechanisms

Cited by 63

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Schnell, D., Buschke, S., Fuchs, H., Gansser, D., Goeldner, R.-G., Uttenreuther-Fischer, M., Stopfer, P., Wind, S., Petersen-Sylla, M., Halabi, A., et al. (2014) · Cancer Chemotherapy and Pharmacology

Pharmacogenetics and Drug MetabolismHER2/EGFR in Cancer Research

Cited by 44

No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone

Richeldi, L., Fletcher, S., Adamali, H., Chaudhuri, N., Wiebe, S., Wind, S., Hohl, K., Baker, A., Schlenker-Herceg, R., Stowasser, S., et al. (2019) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacogenetics and Drug Metabolism

Cited by 34

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

Wiebe, S., Schnell, D., Külzer, R., Gansser, D., Weber, A., Wallenstein, G., Halabi, A., Conrad, A., & Wind, S. (2017) · European Journal of Drug Metabolism and Pharmacokinetics

Pharmacogenetics and Drug MetabolismLung Cancer Treatments and Mutations

Cited by 24